Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01484925 · ClinicalTrials.gov registry record

BETERNet Notch Signaling and Novel Biomarkers for Barretts Esophagus

A clinical trial of Barrett's Esophagus, sponsored by Abramson Cancer Center at Penn Medicine.

Completed
Registry status
60
Enrollment target
1
Study location

NCT01484925 is a study of Barrett's Esophagus that has completed, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 60 participants, below the 522-participant average among 22 other Barrett's Esophagus trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01484925, a study of Barrett's Esophagus, has completed, sponsored by Abramson Cancer Center at Penn Medicine.

COMPLETED
Registry status
60 participants
Enrollment target
1
Study location

Study Summary

This research study hopes to identify new molecular markers in the tissue of Barrett's esophagus that will help physicians better understand and manage this condition. Patients undergoing an upper endoscopy will be asked to complete a gastroesophageal reflux disease (GERD) questionnaire, provide a blood sample and allow additional biopsies to be taken during the procedure.

Conditions Studied

Study Locations (1)

Pennsylvania

  • Abramson Cancer Center - Philadelphia

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2011-11
Est. Completion 2018-11

What the Registry Record Tells You About NCT01484925

The ClinicalTrials.gov registry entry for NCT01484925 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 522-participant average among 22 other Barrett's Esophagus trials with a reported enrollment target (89% lower). The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Barrett's Esophagus appearing as the primary indexed condition, and to 0 interventions.

NCT01484925 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT01484925 about?

NCT01484925 is a clinical study titled "BETERNet Notch Signaling and Novel Biomarkers for Barretts Esophagus". This research study hopes to identify new molecular markers in the tissue of Barrett's esophagus that will help physicians better understand and manage this condition. Patients undergoing an upper endoscopy will be asked to complete a gastroesophageal reflux disease (GERD) questionnaire, provide a b...

What is the current status of trial NCT01484925?

This trial is currently completed. The enrollment target is 60 participants. The study started on 2011-11. Estimated completion is 2018-11.

What conditions does trial NCT01484925 study?

This clinical trial studies the following conditions: Barrett's Esophagus.

Who is sponsoring clinical trial NCT01484925?

This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01484925 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Barrett's Esophagus

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.